Latest Herceptin news
Neratinib Not Superior to Trastuzumab in ERBB2-Breast CA
posted April 15th
by modernClinician Editorial Team
by modernClinician Editorial Team
Neratinib-paclitaxel is no better than trastuzumab-paclitaxel for progression-free survival in recurrent and/or metastatic ERBB2-positive breast cancer, although it may delay the onset and reduce the frequency of central nervous system progression, according to a study published online April 14 in JAMA Oncology.
Lapatinib + Trastuzumab May Rapidly Shrink Breast Tumors
posted March 10th
by modernClinician Editorial Team
by modernClinician Editorial Team
The drug combination of lapatinib (Tykerb) and trastuzumab (Herceptin) induces tumor regression or disappearance in 25 percent of human epidermal growth factor receptor 2 (HER2)-positive cancers in 11 days, according to research presented Thursday at the European Breast Cancer Conference, held from March 9 to 11 in Amsterdam.
Editor's Recommendations
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy .jpg)
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers 
Gap Found Between Awareness of Breast Cancer Risk and Risk-Reducing Behavior 
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions Related Articles
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis 
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing 
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria 
Polypharmacy of Prescription Medications Increased for U.S. Older Adults Monthly Specialist Briefings
Stay Connected
